HemoStyp® Human Trial Results Article Submitted to American Journal of Surgery

HENDERSON, Nev.--(BUSINESS WIRE)--United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp, an Oxidized Regenerated Cellulose, today announced that four surgeons who participated in the recently completed human clinical trial for HemoStyp have prepared and submitted an article entitled Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting to the American Journal of Surgery for peer review. This article is authored by Raymond Schaerf, MD, Sasan Najibi, MD, John Conrad, MD and UHP medical director Gerard Abate MD. This journal submission will highlight the results of aforementioned study showing HemoStyp’s superiority to Surgicel®. Assuming that it obtains peer review approval, the paper will be published and later presented at an upcoming medical conference.

Separately, UHP announced that it has added NikFix® (for use in minor cuts when shaving for both men and women), to its existing Hemostrip® and BooBoo Strip® product lines. The products are currently offered via Walmart Marketplace and can be purchased via the link below:

https://www.walmart.com/search/?query=hemostyp

About United Health Products

United Health Products develops technology; manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The product, HemoStyp, is derived from oxidized regenerated cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.

For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.